gesunheitpfleges.org



St. Jude ICU honored with Beacon Award for Critical Care Excellence for second consecutive year

September 10, 2015

A graduate of Mount Sinai School of Medicine, Dr. DiFeo's laboratory interests are focused on uncovering novel ways to improve the detection and treatment of ovarian cancer with a specific interest in understanding the mechanisms of ovarian cancer chemoresistance. The overall goal of the laboratory is to identify novel biomarkers of ovarian cancer therapeutic response and generate novel targeted molecular therapies that can work alone or in conjunction with current treatment options to combat ovarian cancer. In addition to her 2010 Liz Tilberis Award from OCRF, she was the recipient of the American Association of Cancer Research AstraZeneca Scholar-in-Training Award in 2008, and has also recently received a research grant from the Department of Defense.

Liz Tilberis was a fashion icon and editor-in-chief of Harper's Bazaar. The grant was established in her name in 2000, the year after she died of ovarian cancer. A national organization with headquarters in New York, OCRF is the largest private non-profit organization in the United States dedicated exclusively to funding ovarian cancer research. To date, OCRF has awarded 164 grants for ovarian cancer research, an investment of nearly $40 million.

Ovarian cancer is the deadliest of all gynecologic cancers and is the fifth leading cause of cancer death in women. Worldwide, about 200,000 women are diagnosed with ovarian cancer and 125,000 women die from this disease. In the United States alone, there will be approximately 22,000 new cases of ovarian cancer in the United States each year, and about 15,500 women will die of the disease. Currently there is no effective means of early detection.

Source: The Mount Sinai Hospital / Mount Sinai School of Medicine